TWI800552B - 介白素2受體β(IL2Rβ)/共同γ鏈抗體 - Google Patents

介白素2受體β(IL2Rβ)/共同γ鏈抗體 Download PDF

Info

Publication number
TWI800552B
TWI800552B TW107139964A TW107139964A TWI800552B TW I800552 B TWI800552 B TW I800552B TW 107139964 A TW107139964 A TW 107139964A TW 107139964 A TW107139964 A TW 107139964A TW I800552 B TWI800552 B TW I800552B
Authority
TW
Taiwan
Prior art keywords
il2rbeta
chain antibodies
gamma chain
common gamma
common
Prior art date
Application number
TW107139964A
Other languages
English (en)
Other versions
TW201922785A (zh
Inventor
彼得 包爾
約翰 寇那里
理查 霍普金斯
俊云 賴
建榮 劉
家偉 陳
正一 汪
書平 姚
Original Assignee
新加坡科技研究局
新加坡商優其洛伊生物私人有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新加坡科技研究局, 新加坡商優其洛伊生物私人有限公司 filed Critical 新加坡科技研究局
Publication of TW201922785A publication Critical patent/TW201922785A/zh
Application granted granted Critical
Publication of TWI800552B publication Critical patent/TWI800552B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW107139964A 2017-11-10 2018-11-09 介白素2受體β(IL2Rβ)/共同γ鏈抗體 TWI800552B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SG10201709289S 2017-11-10
SG10201709289S 2017-11-10
US201862652501P 2018-04-04 2018-04-04
US62/652,501 2018-04-04
US201862735347P 2018-09-24 2018-09-24
US62/735,347 2018-09-24

Publications (2)

Publication Number Publication Date
TW201922785A TW201922785A (zh) 2019-06-16
TWI800552B true TWI800552B (zh) 2023-05-01

Family

ID=64362498

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107139964A TWI800552B (zh) 2017-11-10 2018-11-09 介白素2受體β(IL2Rβ)/共同γ鏈抗體

Country Status (7)

Country Link
US (3) US11739157B2 (zh)
EP (1) EP3707162A1 (zh)
JP (2) JP7269249B2 (zh)
CN (1) CN111954680B (zh)
SG (1) SG11202004172UA (zh)
TW (1) TWI800552B (zh)
WO (1) WO2019092181A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50059A (fr) * 2016-11-10 2019-09-18 Medimmune Llc Molécules de liaison spécifiques d'asct2 et leurs utilisations
TW202031683A (zh) * 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202039557A (zh) * 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
JP2023510871A (ja) * 2020-01-14 2023-03-15 シンセカイン インコーポレイテッド Ｉｌ２ムテイン
CA3174786A1 (en) 2020-04-10 2021-10-14 Sayantan Mitra Activatable cytokine constructs and related compositions and methods
CA3211924A1 (en) 2021-03-16 2022-09-22 Sayantan Mitra Masked activatable cytokine constructs and related compositions and methods
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
CN118251416A (zh) * 2021-11-02 2024-06-25 上海岸迈生物科技有限公司 抗cd122抗体、抗cd132抗体及相关的双特异性结合蛋白
CN117700554B (zh) * 2023-08-03 2024-07-12 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗人源cd132的单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323027B1 (en) * 1996-05-10 2001-11-27 Biogen, Inc. Common gamma chain monoclonal antibody blocking agents
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
TW201713699A (zh) * 2015-08-06 2017-04-16 新加坡科技研究局 介白素２受體β（ＩＬ２Ｒβ）／共同γ鏈抗體

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535789D1 (de) 1995-01-09 2008-08-28 Boehringer Ingelheim Int Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
CA2965960A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323027B1 (en) * 1996-05-10 2001-11-27 Biogen, Inc. Common gamma chain monoclonal antibody blocking agents
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
TW201713699A (zh) * 2015-08-06 2017-04-16 新加坡科技研究局 介白素２受體β（ＩＬ２Ｒβ）／共同γ鏈抗體

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Lin Zhang et al., "Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients", Oncotarget, Vol. 7, No. 28, 無, 07 June 2016, pages 43604-43615 *

Also Published As

Publication number Publication date
CN111954680B (zh) 2024-03-15
US20220251221A1 (en) 2022-08-11
CN111954680A (zh) 2020-11-17
US11739157B2 (en) 2023-08-29
JP2023099051A (ja) 2023-07-11
EP3707162A1 (en) 2020-09-16
US20240026016A1 (en) 2024-01-25
JP2021502116A (ja) 2021-01-28
SG11202004172UA (en) 2020-06-29
JP7269249B2 (ja) 2023-05-08
WO2019092181A1 (en) 2019-05-16
TW201922785A (zh) 2019-06-16
US20240052046A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
EP3589313A4 (en) ANTI-TIGITE ANTIBODY
TWI800552B (zh) 介白素2受體β(IL2Rβ)/共同γ鏈抗體
PT3328894T (pt) Anticorpos de cadeia comum gama/il2rbeta
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
IL280780A (en) Anti-TIGIT antibodies
EP3334763A4 (en) NOVEL ANTI-PD-1 ANTIBODIES
IL279352A (en) IL-11RA antibodies
IL280013A (en) Anti-IL36R antibodies
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
EP3606961B8 (en) Garp-tgf-beta antibodies
EP3684806A4 (en) NEW ANTI-CD3EPSILON ANTIBODIES
IL278010A (en) Antibodies to galectin 10
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODIES
EP3512885A4 (en) ANTI-PD-1 ANTIBODY
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
IL277030A (en) Antibodies
EP3596126A4 (en) NEW ANTI-TRKB ANTIBODIES
EP3684820A4 (en) NOVEL ANTI-CD19 ANTIBODIES
GB202110263D0 (en) Anti-btla antibodies
EP3253793A4 (en) Anti-surrogate light chain antibodies
AU2019361253A1 (en) Anti-synuclein antibodies
IL281594A (en) Antibodies against KLRG1
EP3693013A4 (en) BISPECIFIC ANTIBODY
EP3579879A4 (en) ANTI-BODY ANTI-KIR3DL1
GB201806084D0 (en) Antibodies